Actively Recruiting
Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET) in Patients With Cancer
Led by Barbara Ann Karmanos Cancer Institute · Updated on 2025-07-08
N/A
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
B
Barbara Ann Karmanos Cancer Institute
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying the use of 3'-deoxy-3'-[18F] fluorothymidine (FLT) positron emission tomography (PET) imaging in patients with cancer. This phase I trial aims to evaluate how well FLT PET imaging measures tumor growth and the activity of the DNA synthetic pathway in various cancers, including solid tumors and blood cancers. The study also seeks to determine how effective this imaging method is at detecting lesions and assessing response to treatment. Participants receive up to four FLT PET imaging procedures. During each procedure, a small amount of the FLT tracer compound is injected into the vein, followed by PET scan data collection for two hours to measure tumor growth. Blood samples may be taken during the scans, and urine samples collected afterward to analyze breakdown products of the tracer. Throughout the study, patients undergo assessments including PET or CT PET scans to measure tracer uptake and retention in tumors and normal organs. Researchers also evaluate changes in key enzymes related to DNA synthesis before and after therapy. These evaluations help monitor tumor activity and treatment response. The total time participants spend in the scanner during imaging is up to two hours per session, with a focus on capturing detailed tumor growth information.
CONDITIONS
Brief Title
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed solid tumor or hematologic malignancy
- Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging
- Able to lie still in the PET scanner
- Body girth and weight suitable to enter the PET scanner gantry
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
You will not qualify if you...
- Pregnant or nursing
- Unable to lie still in the PET scanner
- Body size unsuitable for PET scanner gantry
- Positive pregnancy test
- Fertile patients not using effective contraception
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - As scheduled up to 4 imaging sessions
Participants undergo up to four 3'-deoxy-3'-[18F] fluorothymidine PET imaging procedures to measure tumor growth.
Up to 4 imaging visits (in-person)
Trial Site Locations
Total: 1 location
1
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201-1379
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here